Governance is the structure that makes quality survivable.

Governance is the centre · the structural gate every trial domain passes through. QMS, ALCOA+, ICH Q9(R1), ISO/IEC 42001 — the policy layer that makes the science survivable on inspection day. Click a node to open that space.

Most regulated organisations treat governance as a regulatory burden — a tax extracted by inspectors and auditors. That frame is correct but incomplete. Governance has three frames simultaneously, and only the third is what makes a company defensible against AI failure modes, regulatory shifts, and the next decade of compliance pressure.

Quality management systems in regulated life sciences are not a single document. They are a layered stack of standards, each binding in a different way and covering a different surface. The stack reads top-down: from the abstract management-system principles to the concrete trial-conduct or device-design rules.

Compliance is shaped by the type of product the organisation makes. The four quadrants below carry distinct standards, distinct inspection regimes, and distinct failure modes. Most regulated organisations live in two or three of them at once · the bridges between them are where audit findings concentrate.

ALCOA was the FDA-articulated data-integrity acronym from the early 1990s. ALCOA+ added five more in 2010 to address the failures the original framework couldn't see: missing context, unstable storage, hidden information. Every regulated computer system must demonstrate ALCOA+ to pass inspection. This is the data integrity floor — not the ceiling.

Inspection readiness is not a state, it's a posture. The percentages below are iFeed's analysis of publicly available 2025 FDA bioanalytical 483s and Warning Letters (FDA does not publish category-level breakdowns); equivalent EU MDR / EMA / PMDA findings cluster around the same surfaces. The cited rule is rarely the underlying problem · the inspector's actual concern is whether the system can be read by another competent reviewer in the inspector's place.

ICH Q9(R1) (Step 4 reached 18 January 2023) is the most-cited ICH document in 2024-2026 inspections. The R1 revision explicitly addressed subjectivity-management, knowledge-base risk, and digitalisation — gaps the 2005 original couldn't anticipate. Every regulated change, deviation, transfer, and validation now passes through the same five-step lifecycle.

AI deployment in regulated life sciences is no longer optional — peak detection algorithms are in every LC-MS/MS instrument, eligibility-screening models triage clinical-trial recruitment, image-classifier SaMDs are FDA-cleared, generative LLMs are inside pharmacovigilance triage. The regulatory text catching up to this reality is split across four standards, each binding in a different way. iFeed's AI quality governance practice operates inside this stack.

The patterns below are the recurring failure modes iFeed sees across regulated organisations — across pharma, MedTech, combination products, and AI-in-regulated. Most are not technical defects. They are governance defects that express themselves through technical findings.

The structures above are how the field describes governance. the methodology is how iFeed operates governance — the methodology that turns the QMS stack, the compliance topology, ALCOA+, Q9(R1), and ISO/IEC 42001 into a single deployable practice. Three phases: Pre-immunisation (vaccination · before AI deployment), Active immunity (operational governance · during use), Adaptive immunity (post-incident learning · after every event).

Governance has internal stakeholders (who owns it, who runs it) and external stakeholders (who inspects it, who funds it, who is affected). The map below is who fires which lever when the system is challenged. Most governance failures sit at the interfaces between these stakeholders, not inside any one role.